Standard BioTools Inc. Debt Securities, Available-for-sale, Amortized Cost
Standard BioTools Inc. (LAB) had Debt Securities, Available-for-sale, Amortized Cost of $527.95 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $527.95M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $505.46M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $170.52M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $186.47M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $527.95M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $505.46M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $170.52M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $186.47M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $211.75M 10-Q · filed 2025-08-15 |
| 2025-03-31 | $237.30M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $270.91M 10-K · filed 2026-03-16 |
| 2024-09-30 | $340.56M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $158.65M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $199.63M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $98.55M 10-K · filed 2025-03-11 |
| 2023-09-30 | $115.62M 10-Q · filed 2023-11-07 |
| 2022-12-31 | $138.87M 10-K · filed 2024-03-01 |
| 2019-09-30 | $64.79M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $70.87M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $75.13M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $95.40M 10-Q · filed 2019-11-08 |
| 2018-09-30 | $35.83M 10-Q · filed 2018-11-06 |
| 2017-12-31 | $63.14M 10-K · filed 2019-03-18 |
| 2016-06-30 | $59.23M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |